Cardiovascular Device M&A: Why CV Leads All Medtech Deal Flow

Cardiovascular Devices Are the Center of Gravity for Medtech M&A

If there is a single segment defining the current era of medical device dealmaking, it is cardiovascular. The numbers tell the story: of the top 10 medtech M&A transactions in 2025-2026, cardiovascular and neurovascular deals account for a disproportionate share of total deal value. The global cardiovascular devices market reached approximately $60 billion in 2025 and is projected to exceed $120 billion by 2032-2033, growing at a CAGR of 7.7-7.8%.

But market size alone does not explain why cardiovascular leads all medtech deal flow. The real drivers are a combination of:

1. Explosive growth in specific subsegments — Pulsed field ablation (PFA) grew 80%+ year-over-year at Medtronic; Boston Scientific's FARAPULSE drove 35% EP revenue growth in Q4 2025
2. Favorable reimbursement dynamics — Cardiovascular procedures have established, generous payment structures that de-risk acquisition economics
3. Aging demographics — Cardiovascular diseases remain the leading cause of death globally, and procedure volumes are rising as populations age
4. Technology platform convergence — AI diagnostics, robotic-assisted intervention, and novel energy modalities (PFA, histotripsy) are creating new product categories that attract strategic acquirers

This article tracks every major cardiovascular device deal in 2025-2026, analyzes the strategic rationale behind each transaction, and identifies where the next wave of CV M&A is heading.

The Mega-Deals: Reshaping Cardiovascular Market Structure

Stryker / Inari Medical — $4.9B (January 2025)

Stryker's acquisition of Inari Medical for $4.9 billion ($80/share) — announced in January 2025 and closed in February — was the opening salvo in the current CV M&A cycle.

What Stryker bought: Inari Medical developed mechanical thrombectomy devices for venous thromboembolism (VTE), including pulmonary embolism (PE) and deep vein thrombosis (DVT). Inari's ClotTriever and FlowTriever systems were category-defining products in a segment with strong procedure volume growth.

Strategic rationale: Stryker, historically an orthopedic and surgical technology company, used the Inari deal to make a major entry into the vascular intervention market. The acquisition gave Stryker immediate scale in a high-growth segment (the global thrombectomy devices market is estimated at approximately $1.75 billion in 2025, growing at ~7% annually) and positioned it to compete with Medtronic and Boston Scientific in interventional cardiology.

Market impact: The Stryker/Inari deal set off a chain reaction. It validated the thrombectomy market's strategic value and directly triggered Boston Scientific's subsequent $14.5 billion acquisition of Penumbra — Inari's closest competitor.

Boston Scientific / Penumbra — $14.5B (January 2026)

Boston Scientific's agreement to acquire Penumbra for $14.5 billion ($374/share) — announced January 15, 2026 — is the second-largest medtech deal on record for the company and the most significant cardiovascular acquisition in recent memory.

What Boston Scientific is buying: Penumbra has developed a comprehensive portfolio of mechanical thrombectomy and neurovascular devices for treating:

• Pulmonary embolism
• Stroke
• Deep vein thrombosis
• Acute limb ischemia
• Heart attack
• Aneurysms

Penumbra expected approximately $1.4 billion in 2025 revenue, representing 17.3-17.5% year-over-year growth — and Q4 2025 revenue growth accelerated to 21.4-22%.

Deal structure: The transaction is structured as 73% cash and 27% stock ($374/share), with Boston Scientific financing the approximately $11 billion cash portion through existing reserves and new debt. The deal is expected to close in 2026, pending shareholder approval.

Strategic rationale: Boston Scientific CEO Mike Mahoney described Penumbra as having "a highly differentiated portfolio of novel technologies that operate in high-growth segments where Boston Scientific lacks offerings." The deal:

• Re-enters neurovascular — Boston Scientific divested its neurovascular business to Stryker in 2011 for $1.5 billion. Fourteen years later, it is re-entering at 10x the price, reflecting how much the segment has grown.
• Responds to Stryker/Inari — With Stryker having acquired Inari, Penumbra became the last major independent thrombectomy platform. As analysts noted, "Since Stryker acquired Inari Medical in early 2025, the conventional thinking was that Penumbra would go next."
• Complements existing CV portfolio — Penumbra's thrombectomy platform pairs with Boston Scientific's existing drug-eluting stents, drug-coated balloons, and other interventional devices, enabling cross-selling across interventional cardiology relationships.

Financial impact: Boston Scientific estimates modest near-term dilution (~$0.06-0.08 per share in the first full year) but expects the transaction to be neutral to slightly accretive by year two.

Medtronic / CathWorks — $585M (February 2026)

Medtronic announced on February 3, 2026, that it would exercise its option to acquire CathWorks for $585 million (with potential undisclosed earn-out payments post-acquisition that could bring total consideration to approximately $1 billion).

What Medtronic bought: CathWorks' FFRangio system is an AI-powered platform that uses computational science to deliver fractional flow reserve (FFR) measurements across the entire coronary artery tree from standard angiograms — eliminating the need for invasive pressure wires. Traditional wire-based FFR measurement is invasive, requires more time, more radiation exposure, and higher costs, limiting its adoption.

Strategic rationale: The acquisition follows a 2022 strategic partnership and co-promotion agreement. CathWorks CEO Ramin Mousavi noted the company "came very close to not existing" during COVID-19 before reworking its technology. Medtronic SVP Jason Weidman stated the deal allows Medtronic to "transform the cath lab with a technology that provides real-time data, informs individualized treatment approaches, and drives new standards of care."

The deal mirrors Philips' acquisition of SpectraWAVE in December 2025, which similarly on-boarded wire-free FFR technology — signaling that the major players see non-invasive coronary artery disease (CAD) evaluation as the future of the cath lab.

Integration advantage: Medtronic's existing coronary stent portfolio (Resolute Onyx, Onyx Frontier drug-eluting stents) pairs naturally with CathWorks' diagnostic system, creating an integrated diagnosis-to-treatment workflow.

The PFA Revolution: Driving CV Growth and M&A

Pulsed field ablation (PFA) for atrial fibrillation treatment has become the single hottest product category in medtech — and a major catalyst for cardiovascular M&A and investment.

What Is PFA?

PFA uses short, high-voltage electrical pulses to selectively destroy cardiac tissue causing atrial fibrillation (AFib), while sparing surrounding structures. This tissue selectivity represents a major advantage over traditional radiofrequency (RF) and cryoablation methods, which can cause collateral injury to the esophagus, phrenic nerve, and other adjacent structures.

Market Size and Growth

The PFA market is growing at extraordinary rates:

• Medtronic's Cardiac Ablation Solutions grew 80% year-over-year in Q3 FY2026 (ending January 2026), including 137% growth in the U.S. — driven almost entirely by its Affera PFA portfolio
• Boston Scientific's FARAPULSE drove 35% EP revenue growth in Q4 2025
• J&J's electrophysiology business helped drive 15.2% cardiovascular growth for the full year
• The global PFA market is projected to grow at a 24.2% CAGR through 2035

The PFA Competitive Landscape

Five major companies are now competing in U.S. PFA:

PFA-Related M&A and Investment

Kardium's $250 million raise in July 2025 (following a $104 million round in June 2024) is the most significant VC-backed PFA investment outside the majors. The company's Globe system for pulsed field ablation showed 78% effectiveness in patients with intermittent AFib in its Pulsar trial, with no device-related safety events.

As the PFA market matures, expect further consolidation as one or more of the smaller PFA players are acquired by the majors to expand catheter portfolios, add differentiated energy delivery mechanisms, or acquire clinical data assets.

Structural Heart: TAVR Expansion and Beyond

The $15.7B Market

The global heart valve devices market is estimated at $15.7 billion in 2026, projected to reach $31.9 billion by 2033 at a 10.7% CAGR. North America leads with 41% market share, while Asia Pacific is the fastest-growing region at 32% share.

Key Structural Heart Deals

J&J MedTech completed its $13.1 billion acquisition of Shockwave Medical in 2024, gaining leadership in intravascular lithotripsy (IVL) technology for treating calcified coronary and peripheral arterial disease — one of the largest cardiovascular device deals in history and a clear signal of J&J's cardiovascular ambitions.

Edwards Lifesciences remains the dominant TAVR player, though its attempted acquisition of JenaValve for $1.2 billion was blocked by the FTC in January 2026 (see our separate analysis). Despite the deal's failure, JenaValve's Trilogy transcatheter heart valve subsequently received FDA PMA approval in March 2026 for aortic regurgitation — validating the technology the FTC sought to protect from monopolistic acquisition. Edwards also moved to fully acquire Vectorious Medical for $497 million, building on its earlier purchase of Endotronix to expand in heart failure remote monitoring.

Medtronic invested $90 million in Anteris Technologies (acquiring a 16% stake) for the DurAVR TAVR device development in January 2026, and also partnered with DASI Simulations in October 2025 for AI-powered personalized TAVR planning. In the structural heart space, Abbott, Medtronic, and Edwards collectively hold a combined market share above 70%.

W.L. Gore announced the acquisition of Conformal Medical in January 2026, adding the CLAAS AcuForm system for left atrial appendage (LAA) occlusion to its portfolio.

4C Medical received a $175 million investment led by Boston Scientific in March 2025 for its heart valve technology.

The Neurovascular Opportunity

Neurovascular devices — including stroke treatment, aneurysm management, and brain access technologies — represent a rapidly growing subsegment of the broader cardiovascular deal landscape.

Medtronic / Scientia Vascular — ~$550M (March 2026)

Medtronic agreed to acquire Scientia Vascular for approximately $550 million in March 2026, advancing its navigation capabilities in complex neurovascular procedures. This deal follows Medtronic's existing Solitaire device franchise and positions it to compete more effectively with Boston Scientific/Penumbra in stroke treatment.

The Neurovascular Competitive Landscape

With Boston Scientific's $14.5B Penumbra acquisition creating a neurovascular powerhouse and Stryker having acquired Inari, the neurovascular M&A landscape is consolidating rapidly. The thrombectomy devices market's neurovascular applications account for roughly 45% of the total ~$1.75 billion market, with pulmonary embolism treatment representing the fastest-growing segment.

Why CV Leads All Medtech Deal Flow: The Structural Advantages

1. Revenue Growth Outpaces All Other Segments

Cardiovascular portfolios are consistently the fastest-growing segments for the major medtech companies:

• Medtronic: Cardiovascular portfolio revenue reached $3.457 billion in Q3 FY2026, up 13.8% as reported and 10.6% organic — the company's strongest cardiovascular revenue growth in over a decade
• Boston Scientific: CV segment continues to be the company's growth engine, with interventional cardiology and EP leading the way
• J&J MedTech: Cardiovascular segment grew 15.2% for the full year 2025, the standout performer in the MedTech division
• Edwards Lifesciences: TAVR remains the company's core growth driver, even as it explores transcatheter mitral and tricuspid valve opportunities

2. Favorable Reimbursement and Procedure Volume Dynamics

Cardiovascular procedures benefit from:

• Established reimbursement codes with favorable payment rates
• Growing procedure volumes driven by aging populations worldwide
• Expanding indications — TAVR moving into aortic regurgitation, PFA expanding from paroxysmal to persistent AFib, thrombectomy gaining evidence for new vessel territories
• Value-based care alignment — CV procedures have strong, measurable outcomes data

3. Technology Convergence Creates New Product Categories

The intersection of three technology waves is creating entirely new product categories:

• AI + diagnostics — CathWorks' FFRangio, HeartFlow PCI Navigator, Philips' SpectraWAVE
• Robotics + intervention — Siemens Healthineers Corindus, Telos Health, XCath for vascular robotics
• Novel energy modalities — PFA for ablation, HistoSonics for histotripsy, acoustic liquefaction (Petal Surgical)

Each convergence point creates acquisition targets that command premium valuations because they offer differentiated technology platforms, not just incremental product improvements.

4. Venture Capital Is Concentrated in CV

According to EY's Pulse of the MedTech 2025 report, companies in the cardiovascular space captured six of the top 10 U.S. VC rounds and two of the top 10 European rounds. VC investment in medtech surged 16% in 2025, with cardiovascular and robotics as the top therapeutic areas.

The Complete CV M&A Deal Tracker: 2025-2026

What Is Next for Cardiovascular M&A

Deals to Watch

1. PFA consolidation — With Medtronic, Boston Scientific, J&J, Abbott, and Kardium all competing, the market cannot sustain five major PFA platforms long-term. Expect one or more acquisitions as the market matures and share dynamics crystallize by mid-2026.

2. Structural heart pipeline deals — The mitral and tricuspid valve repair/replacement market is still early-stage, with multiple clinical-stage companies (including 4C Medical) that could be acquisition targets as pivotal trial data matures.

3. AI-enabled cath lab platforms — Following Medtronic/CathWorks and Philips/SpectraWAVE, other AI-enabled coronary diagnostic companies are potential targets for Abbott, Stryker, or J&J.

4. Vascular robotics — As stroke and PE treatment becomes more procedure-intensive, robotic-assisted vascular intervention platforms (Corindus, XCath) could attract strategic interest from companies seeking to differentiate on procedural precision.

Valuation Dynamics

According to PwC's US Deals 2026 outlook, high-growth CV categories such as structural heart, peripheral vascular intervention, neurovascular, and specialized diagnostics continue to trade at notable valuation premiums, while more mature categories have stabilized. The medtech industry recorded $92.8 billion in announced deal value through November 30, 2025 — the highest level in more than a decade — with cardiovascular accounting for a disproportionate share.

Risk Factors

• Tariff uncertainty — An estimated $400M+ in tariff impact is priced into many medtech guidance ranges; any policy shift could alter earnings trajectories
• FTC scrutiny — Further cardiovascular consolidation (particularly in thrombectomy or PFA) may trigger antitrust review, as the Edwards/JenaValve case demonstrated
• China market recalibration — Volume-based procurement policies in China continue to pressure pricing and margins for CV devices

The Bottom Line

Cardiovascular devices dominate medtech M&A because they sit at the intersection of demographic tailwinds, technological innovation, and favorable reimbursement dynamics. With over $20 billion in CV-related deals announced in the 15 months from January 2025 through March 2026, the pace shows no signs of slowing.

For medtech strategics, the imperative is clear: own the patient pathway from diagnosis to treatment, across multiple cardiovascular conditions, in both hospital and outpatient settings. The companies that assemble the most complete cardiovascular platforms — combining interventional devices, AI diagnostics, robotic-assisted procedures, and novel energy modalities — will define the next decade of medtech growth.